Study of Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes

NCT01017731 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
Solid Tumor

Interventions

BIOLOGICAL: IMC-1121B
DRUG: Moxifloxacin
DRUG: Diphenhydramine

Sponsor

Eli Lilly and Company